Cargando…

Analysis of combined deficiency of interleukin-1 and -6 versus single deficiencies in TNF-mediated arthritis and systemic bone loss

AIMS: Insufficient treatment response in rheumatoid arthritis (RA) patients requires novel treatment strategies to halt disease progression. The potential benefit of combination of cytokine-inhibitors in RA is still unclear and needs further investigation. To explore the impact of combined deficienc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayer, Silvia, Niederreiter, Birgit, Kalkgruber, Marlene, Wanic, Konrad, Maißner, Julia, Smolen, Josef S., Aletaha, Daniel, Blüml, Stephan, Redlich, Kurt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Editorial Society of Bone & Joint Surgery 2022
Materias:	Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350695/ https://www.ncbi.nlm.nih.gov/pubmed/35801532 http://dx.doi.org/10.1302/2046-3758.117.BJR-2021-0481.R1

Ejemplares similares

Combined depletion of interleukin-1 and interleukin-6 does not exceed single depletion of interleukin -1 in TNF-mediated arthritis
por: Hayer, Silvia, et al.
Publicado: (2012)

Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis
por: Borst, Carina, et al.
Publicado: (2021)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
por: Lopez-Romero, Pedro, et al.
Publicado: (2022)

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2019)

Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2020)

Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce
por: De Marco, Gabriele, et al.
Publicado: (2023)

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis
por: Gärtner, M, et al.
Publicado: (2016)

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Primary antibody deficiency-associated arthritis shares features with spondyloarthritis and enteropathic arthritis
por: Pott, Nina Mee, et al.
Publicado: (2022)

CCR6 controls autoimmune but not innate immunity‐driven experimental arthritis
por: Bonelli, Michael, et al.
Publicado: (2018)

Genetic deficiency of Syk protects mice from autoantibody-induced arthritis
por: Jakus, Zoltán, et al.
Publicado: (2010)

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
por: Norvang, Vibeke, et al.
Publicado: (2018)

Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature
por: Karonitsch, Thomas, et al.
Publicado: (2022)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
por: Feist, Eugen, et al.
Publicado: (2022)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Brief Report: Deficient Thymic Output in Rheumatoid Arthritis Despite Abundance of Prethymic Progenitors
por: Wagner, Ulf, et al.
Publicado: (2013)

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study
por: Smolen, Josef S, et al.
Publicado: (2019)

Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
por: Ramiro, Sofia, et al.
Publicado: (2015)

Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Contrasting contributions of TNF from distinct cellular sources in arthritis
por: Kruglov, Andrey, et al.
Publicado: (2020)

Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
por: Smolen, Josef S, et al.
Publicado: (2021)

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
por: Kussmann, Manuel, et al.
Publicado: (2021)

Cartilage damage and bone erosion are more prominent determinants of functional impairment in longstanding experimental arthritis than synovial inflammation
por: Hayer, Silvia, et al.
Publicado: (2016)

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
por: Sigaux, Johanna, et al.
Publicado: (2017)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)
por: Aletaha, Daniel, et al.
Publicado: (2021)

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
por: Smolen, Josef S, et al.
Publicado: (2008)

Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eight–joint Disease Activity Score, C-reactive protein level and patient global assessment
por: Felson, David, et al.
Publicado: (2021)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-TNF in combination with OPG or PTH in TNF-mediated arthritis
por: Redlich, K, et al.
Publicado: (2004)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
por: Smolen, Josef S, et al.
Publicado: (2021)

Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy
por: Ibáñez-Costa, Alejandro, et al.
Publicado: (2022)

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
por: Bouget, Vincent, et al.
Publicado: (2022)

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
por: Gossec, Laure, et al.
Publicado: (2022)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Multimodal [(18)F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNFα Transgenic Mice
por: Hayer, Silvia, et al.
Publicado: (2019)

A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis
por: Mankia, Kulveer, et al.
Publicado: (2021)

Zoledronic acid protects from local and systemic bone loss in TNF-mediated arthritis
por: Zwerina, J, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_ltksefj3v8djo5mmslnolrbrhp